Vaxcyte, Inc.
General ticker "PCVX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $6.6B (TTM average)
Vaxcyte, Inc. follows the US Stock Market performance with the rate: 0.9%.
Estimated limits based on current volatility of 2.5%: low 46.35$, high 48.73$
Factors to consider:
- Total employees count: 414 (+63.0%) as of 2024
- Top business risk factors: Product commercialization failure, Operational and conduct risks, Manufacturing risks, Public perception, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [47.37$, 106.58$]
- 2025-12-31 to 2026-12-31 estimated range: [32.71$, 77.69$]
Financial Metrics affecting the PCVX estimates:
- Negative: with PPE of -22.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.38 <= 0.04
- Positive: Shareholder equity ratio, % of 94.15 > 64.17
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term PCVX quotes
Long-term PCVX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $232.26MM | $468.04MM | $569.55MM |
| Operating Income | $-232.26MM | $-468.04MM | $-569.55MM |
| Non-Operating Income | $8.77MM | $65.78MM | $105.62MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $169.45MM | $332.34MM | $476.64MM |
| Income(Loss) | $-223.49MM | $-402.27MM | $-463.93MM |
| Profit(Loss)* | $-223.49MM | $-402.27MM | $-463.93MM |
| Stockholders Equity | $953.61MM | $1,240.47MM | $3,305.82MM |
| Assets | $1,006.18MM | $1,407.92MM | $3,511.32MM |
| Operating Cash Flow | $-170.60MM | $-296.79MM | $-452.63MM |
| Capital expenditure | $5.84MM | $67.88MM | $22.43MM |
| Investing Cash Flow | $74.58MM | $-773.31MM | $-2,005.67MM |
| Financing Cash Flow | $861.55MM | $639.81MM | $2,448.51MM |
| Earnings Per Share** | $-3.44 | $-4.14 | $-3.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.